Essentra is showcasing its pharmaceutical packaging, labels, serialisation and security portfolio at Pharmapack Europe in Paris this week (February 1-2). The comprehensive range of products underlines the company’s ability to provide advanced solutions in response to current and upcoming industry challenges and legislation.
Essentra develops packaging that increases patient adherence, the process by which users are encouraged to comply with their prescribed medical regime. For example, this may be delivered through products such as the extended content label, which simply and effectively increases labelling space without compromising the size of the packaging, providing patients with more information to ensure medicines are taken correctly.
Attendees at Pharmapack will also see Essentra’s Plurium leaflet which delivers several pages of information in multiple colours and can be set out in an attractive and convenient booklet format, allowing patients to flip through pages and access information about their medications easily.
The company will also exhibit its tamper verification, serialisation and authentication solutions at the international trade show. These layers of security solutions are becoming increasingly important as the EU Falsified Medicines Directive (FMD), commencing February 2019, states that all pharmaceutical companies providing medicines for human consumption must include both a unique identifier and an anti-tampering device on all packaging.
Rupert Taylor, global category manager, healthcare and personal care, said: “With the EU FMD fast approaching, it is essential that the pharmaceutical industry acts now to ensure that all products comply with new legislation and are protected from counterfeiters. The best way to do this is to implement multiple layers of security, featuring tamper verification, authentication and serialisation features.”